截至发稿，王睿累计任职时间10年286天，现任基金资产总规模57.19亿元，任职期间最佳基金回报 253.09%， 任职期间最差基金回报-32.84%。 朱慧灵累计任职时间311天，现任基金资产总规模2.42亿元，任职期间最佳基金回报5.19%， 任职期间 最差基金回报5.1%。 从基金十大重仓股角度 数据显示，中信保诚基金旗下1只基金重仓舒泰神。中信保诚至瑞混合A（003432）四季度增持6万股， 持有股数35.5万股，占基金净值比例为4%，位居第六大重仓股。根据测算，今日浮盈赚取约55.03万 元。连续3天上涨期间浮盈赚取90.17万元。 中信保诚至瑞混合A（003432）成立日期2016年10月21日，最新规模1.34亿。今年以来收益0.45%，同 类排名7442/8873；近一年收益5.69%，同类排名7141/8123；成立以来收益70.61%。 中信保诚至瑞混合A（003432）基金经理为王睿、朱慧灵。 2月6日，舒泰神涨5.65%，截至发稿，报29.00元/股，成交4.37亿元，换手率3.45%，总市值138.55亿 元。舒泰神股价已经连续3天上涨，区间累计涨幅10.2%。 资料显示，舒泰神(北 ...

1月30日，舒泰神涨0.63%，成交额3.95亿元。两融数据显示，当日舒泰神获融资买入额2081.25万元， 融资偿还1760.02万元，融资净买入321.23万元。截至1月30日，舒泰神融资融券余额合计1.33亿元。 融资方面，舒泰神当日融资买入2081.25万元。当前融资余额1.33亿元，占流通市值的1.08%。 融券方面，舒泰神1月30日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元；融 券余量0.00股，融券余额0.00元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 截至9月30日，舒泰神股东户数4.65万，较上期增加46.97%；人均流通股9745股，较上期减少31.98%。 2025年1月-9月，舒泰神实现营业收入1.81亿元，同比减少30.82%；归母净利润-3068.95万元 ...

数据显示，中信保诚基金旗下1只基金重仓舒泰神。中信保诚至瑞混合A（003432）四季度增持6万股， 持有股数35.5万股，占基金净值比例为4%，位居第六大重仓股。根据测算，今日浮亏损失约51.83万 元。 中信保诚至瑞混合A（003432）成立日期2016年10月21日，最新规模1.34亿。今年以来收益1.83%，同 类排名6888/8861；近一年收益7.03%，同类排名6921/8126；成立以来收益72.96%。 中信保诚至瑞混合A（003432）基金经理为王睿、朱慧灵。 1月27日，舒泰神跌5.2%，截至发稿，报26.60元/股，成交3.83亿元，换手率3.13%，总市值127.09亿 元。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 朱慧灵累计任职时间301天，现任基金资产总规模2.42亿元 ...

Group 1 - The core viewpoint of the news is that Shuyou Shen's stock has shown a significant increase in price recently, with a year-to-date increase of 10.65% and a notable rise of 10.65% over the last five trading days [1] - As of January 9, Shuyou Shen's stock price reached 30.23 yuan per share, with a total market capitalization of 14.443 billion yuan [1] - The company primarily engages in the research, production, and sales of biological products and certain chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] Group 2 - As of September 30, the number of shareholders for Shuyou Shen increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, but has not paid any dividends in the last three years [3]

Group 1 - The core viewpoint of the news is that Shutaishen's stock has shown significant volatility, with a year-to-date increase of 275.17% and recent fluctuations in trading volume and price [1][2] - As of December 25, Shutaishen's stock price was 27.80 yuan per share, with a total market capitalization of 13.282 billion yuan [1] - The company has experienced a net outflow of main funds amounting to 23.4642 million yuan, with large orders showing a buy-sell imbalance [1] Group 2 - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the primary revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] - As of September 30, the company reported a revenue of 181 million yuan for the first nine months of 2025, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.6895 million yuan, a decrease of 227.71% [2] - The company has not distributed any dividends in the last three years, with a total payout of 771 million yuan since its A-share listing [3]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.01% on December 23, with a current price of 26.88 yuan per share and a total market capitalization of 12.843 billion yuan. The company has seen significant fluctuations in its stock price throughout the year, with a year-to-date increase of 262.75% but a recent decline over the past 20 and 60 days [1]. Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, representing a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.6895 million yuan, a decline of 227.71% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shuyou Shen was 46,500, an increase of 46.97% from the previous period. The average number of circulating shares per shareholder was 9,745, which decreased by 31.98% [2]. Dividend Distribution - Since its A-share listing, Shuyou Shen has distributed a total of 771 million yuan in dividends. However, there have been no dividend distributions in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Xingshan He Run Mixed A ranked as the third-largest shareholder with 12.2691 million shares, a decrease of 3.4519 million shares from the previous period. Xingshan He Yi Mixed A ranked fifth with 9.3396 million shares, an increase of 3.3875 million shares [3].

Group 1 - The core point of the news is that Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. experienced a stock price increase of 5.14%, reaching 32.30 CNY per share, with a trading volume of 505 million CNY and a turnover rate of 3.52%, resulting in a total market capitalization of 15.432 billion CNY [1] - The company was established on August 16, 2002, and went public on April 15, 2011. Its main business involves the research, production, and sales of biological products and some chemical drugs [1] - The revenue composition of the company includes 59.17% from injectable mouse nerve growth factor (Sutai Shen), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - From the perspective of major fund holdings, one fund under Yinhua Fund has a significant position in Shuyou Shen. The Yinhua Growth Smart Selection Mixed A Fund (024455) held 430,300 shares in the third quarter, accounting for 3.48% of the fund's net value, making it the ninth largest holding [2] - The estimated floating profit from this position today is approximately 679,900 CNY [2] - The Yinhua Growth Smart Selection Mixed A Fund (024455) was established on June 20, 2025, with a current size of 253 million CNY and a cumulative return of 5.31% since inception [3]

数据显示，东方阿尔法基金旗下1只基金重仓舒泰神。东方阿尔法健康产业混合发起A（024357）三季 度增持22.3万股，持有股数23.95万股，占基金净值比例为6.08%，位居第八大重仓股。根据测算，今日 浮亏损失约39.51万元。连续5天下跌期间浮亏损失176.72万元。 东方阿尔法健康产业混合发起A（024357）成立日期2025年6月12日，最新规模3539.51万。成立以来亏 损4.69%。 东方阿尔法健康产业混合发起A（024357）基金经理为孟昱。 11月24日，舒泰神跌5.17%，截至发稿，报30.27元/股，成交3.80亿元，换手率2.67%，总市值144.62亿 元。舒泰神股价已经连续5天下跌，区间累计跌幅18.78%。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 截至发稿，孟昱累计任 ...

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

Core Viewpoint - The stock of Shuyou Shen has shown significant volatility, with a year-to-date increase of 426.05%, but recent performance indicates a mixed trend with a decline over the past 60 days [2]. Group 1: Stock Performance - As of November 14, Shuyou Shen's stock price rose by 2.04% to 38.98 CNY per share, with a trading volume of 9.15 billion CNY and a market capitalization of 186.24 billion CNY [1]. - The stock has experienced a 14.71% increase over the last five trading days, but a 2.31% decrease over the last 20 days and a 23.54% decline over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decrease of 227.71% [2]. - The company has not distributed any dividends in the last three years, with a total payout of 771 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Xingquan Helun Mixed A and an increase by Xingquan Heyi Mixed A [3].